Published 2:46 PM PDT, September 1, 2026
Unicycive Therapeutics, Inc. (NASDAQ:UNCY)
LOS ALTOS, CA, UNITED STATES, September 1, 2026 / EINPresswire.com / -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11 a.m. ET.
Unicycive Therapeutics, Inc. is a B2i Digital Featured Company. See the company’s in-depth profile at: https://b2idigital.com/unicycive
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate-binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment, UNI-494, is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit https://unicycive.com/
Kevin Gardner
LifeSci Advisors
Unicycive Therapeutics
SOURCE: Unicycive Therapeutics, Inc.
David Shapiro
B2i Digital, Inc.
+1 212-579-4844
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.